CKD-EPI creatinine equation (2009)
The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation, especially in patients with higher GFR. This results in reduced misclassification of CKD.
Pētījumu autori: Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, and Coresh J.
Versija: 1.16
  • Publiski
  • Nefroloģija
  • {{ modelType }}
  • Sīkāka informācija
  • Modeļa validēšana
  • Saglabāt ievades datus
  • Slodzes ievade
  • lang lang

Aprēķiniet rezultātu

Iestatiet vairāk parametru, lai veiktu aprēķinu

Estimated GFR: ml/min/1.73m2

{{ resultSubheader }}
{{ chart.title }}
Rezultātu intervāls {{ additionalResult.min }} uz {{ additionalResult.max }}

Nosacījumu informācija

The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation was developed in an effort to create a more precise formula to estimate glomerular filtrate rate (GFR) from serum creatinine and other readily available clinical parameters, especially at when actual GFR is >60 mL/min per 1.73m2.

Researchers pooled data from multiple studies to develop and validate this new equation. They randomly divided 10 studies which included 8254 participants, into separate data sets for development and internal validation. 16 additional studies, which included 3896 participants, were used for external validation.

The CKD-EPI equation performed better than the MDRD (Modification of Diet in Renal Disease Study) equation, especially at higher GFR, with less bias and greater accuracy. When looking at NHANES (National Health and Nutrition Examination Survey) data, the median estimated GFR was 94.5 mL/min per 1.73 m2 vs. 85.0 mL/min per 1.73 m2, and the prevalence of chronic kidney disease was 11.5% versus 13.1%.

{{ file.classification }}
PRO
Piezīme
Piezīmes ir redzamas tikai rezultātu lejuplādētajā versijā un Evidencio tās nesaglabā.

Šis modelis ir paredzēts izglītojošiem, mācību un informatīviem nolūkiem. To nedrīkst izmantot, lai atbalstītu medicīnisku lēmumu pieņemšanu vai sniegtu medicīniskus vai diagnostiskus pakalpojumus. Izlasiet mūsu pilnu disclaimer.

Pamatmodeļi Daļa no
Komentāri
Komentārs
Lūdzu, ievadiet komentāru
Komentāri ir redzami ikvienam

Modeļa atsauksmes

Atgriezeniskās saites vēl nav saņemtas 1 komentārs {{ model.comments.length }} Komentāri
Uz {{ comment.created_at }} {{ comment.user.username }} vairs nereģistrēts autors rakstīja:
{{ comment.content }}
logo

Lūdzu, pierakstieties, lai iespējotu Evidencio drukāšanas funkcijas

Lai izmantotu Evidencio drukāšanas funkcijas, Jums ir jābūt autorizētam.
Ja Jums nav Evidencio kopienas konta, Jūs varat izveidot savu bezmaksas personīgo kontu:

https://www.evidencio.com/registration.

Izdrukāti rezultāti - Piemēri {{ new Date().toLocaleString() }}

Evidencio Kopienas konta priekšrocības

With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

Atruna: Aprēķini vien nekad nedrīkst noteikt pacienta aprūpi, un tie nevar aizstāt profesionālu vērtējumu.
Terms & Conditions | Privacy Policy | Disclaimer | Contact | Refuse cookies |
Evidencio v3.25 © 2015 - 2024 Evidencio. All Rights Reserved